Mishcon de Reya has advised Relation Therapeutics on its $110 million collaboration with GSK. The strategic research collaboration with GSK is focused on generating large-scale human cellular perturbation data and deploying them into models, including MORGAN, Relation's cellular biology foundation model, to deepen understanding of disease biology and support the discovery of potential new therapeutic targets.
This agreement follows from our Life Sciences team work in December 2025 advising Relation Therapeutics on its strategic multi-programme collaboration with Novartis, representing almost $1.7 billion in combined funding and support to propel its AI-powered drug discovery.
Patrick Farrant, Partner and Head of Life Sciences at Mishcon de Reya, commented: "It has been a pleasure and a privilege to work with the amazing team at Relation Therapeutics on this collaboration. Relation is a long-standing client of the firm, and we have been proud to advise them on the expansion of their relationship with GSK, the fourth agreement we've advised on to date".
Our involvement in these deals highlights our commitment to supporting innovative biotechnology companies like Relation Therapeutics in their mission to transform drug discovery and development.
Today's announcement also comes after GSK publicised its relocation to a new research and development centre in Cambridge. Mishcon de Reya is excited to see GSK's commitment to the UK's Golden Triangle, which complements our own vision for operating at the heart of the UK's Innovation Economy across the arc with offices in Oxford, Cambridge and London.
The Mishcon de Reya team was led by Patrick Farrant, who worked with colleagues Dr David Rainford and Sophie Wood.
For our latest insights, subscribe to View from the Arc, our publication celebrating the Golden Triangle and spotlighting innovators’ ambitions.